Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female ≥ 18 years old * Histologically confirmed diagnosis of poorly-differentiated neuroendocrine carcinoma of the gastroenteropancreatic tract or unknown primary * Evidence of measurable disease per RECIST 1.1 on another imagine modality (CT, MRI or FDGPET) with at least 3 tumors \>1cm in largest diameter. CT, MRI or Fluorodeoxyglucose (FDG)-PET must have been performed within 2 months of the study scan. (Of note, participants may sign consent for the study prior to scheduling of said CT, MRI or FDG-PET, but will be considered screen failures if the CT/MRI/FDG-PET does not reveal at least 3 tumors \>1cm). Exclusion Criteria: * Participants with well-differentiated neuroendocrine tumors * Participants who have undergone 68Ga-dotatate PET scan in the past * Pregnant women and/or breastfeeding women. Women of child bearing potential must have a negative pregnancy test prior to scan.